The presence of levodopa-metabolizing bacteria in the intestines of adults using Duodopa (Duopa in the U.S.) to treat their Parkinson’s disease did not affect their blood levels of levodopa, a small study in Japan suggested. Rather, people on this levodopa-carbidopa formulation, administered directly into the small intestine, “can maintain a constant…
A National Institutes of Health (NIH) grant worth $3.2 million will further research into how the rewiring of serotonin-producing nerve cells — a chemical messenger mostly involved in mood, cognition and memory — might help with controlling movement in people with advanced Parkinson’s disease. The grant, given to Christopher…
Although safe and fairly well tolerated, treatment with the over-the-counter supplement mannitol did not lessen symptoms in adults with Parkinson’s disease over 36 weeks, a small Phase 2a clinical trial concluded. Its researchers noted, however, that the study had too few patients to show a statistically significant impact on…
Delve Health and Global Kinetics, two digital healthcare companies, are teaming up to simplify the remote monitoring, data collection and analysis of Parkinson’s disease patients enrolled in clinical studies. “This partnership represents both companies’ commitment to providing Parkinson’s patients quality solutions that are user-friendly within the context of…
People with Parkinson’s disease who regularly eat foods rich in flavonoids — plant-produced metabolites abundant in colorful fruits and plants, from berries and teas to dark chocolate and red wine — have a lower mortality risk than patients who rarely eat these foods, a study that followed people for up to…
Sio Gene Therapies (Sio), formerly known as Axovant, intends to stop  development of AXO-Lenti-PD, an investigational gene therapy for Parkinson’s disease. Sio will return the global rights to develop and market the therapy to Oxford Biomedica, which licensed the treatment to Sio in 2018. The…
The Michael J. Fox Foundation (MJFF) encouraged the U.S. House of Representatives’ Committee on Veterans’ Affairs to expand healthcare access for veterans exposed to hazardous chemicals, and to better support research into service-connected Parkinson’s disease. Recently, the committee hosted a roundtable discussion about healthcare costs for veterans exposed…
Medications used to treat rheumatoid arthritis, an autoimmune disorder, do not affect a person’s risk of developing Parkinson’s disease, a Finnish study, funded by the Michael J. Fox Foundation for Parkinson’s Research, reported. Rheumatoid arthritis has been associated with a lower Parkinson’s risk, but exposure to arthritis therapies did…
A short course of ENT-01, Enterin’s investigational therapy for Parkinson’s disease, appears to restore the function of nerve cells found in the gut to ease constipation. These findings come from KARMET, a Phase 2b clinical trial (NCT03781791) that evaluated ENT-01’s safety when taken once daily for at…
Caraway Therapeutics was awarded a new research grant from the Michael J. Fox Foundation (MJFF) to further work on therapies that increase flux, or movement, into the lysosome, a tiny cell compartment that helps clear away the alpha-synuclein toxic clumps that are known to cause Parkinson’s disease. This…
Get regular updates to your inbox.
